iECURE's ECUR-506 showed promising safety and efficacy in a Phase 1/2 study for neonatal-onset OTC deficiency, with no major safety issues. BMO Capital Markets upgraded Precision BioSciences to ...
- Publication describes how the unique qualities of ARCUS nucleases contribute to precise and efficient gene editing for gene insertion, single base editing, specific small and large deletions, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results